Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized study of nivolumab + ipilimumab versus chemotherapy in advanced non-small cell lung cancer
2017-002842-60Phase 3Completed
- Sponsor
- CHU Rennes
- Start
- Sep 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of nivolumab and ipilimumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by CHU Rennes. Primary endpoint: Overall survival. Started Sep 2017; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2017-002842-60.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002842-60.